|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
|
CA2881057C
(en)
|
2012-08-28 |
2020-10-27 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
EP2890691B1
(en)
*
|
2012-08-31 |
2018-04-25 |
Principia Biopharma Inc. |
Benzimidazole derivatives as itk inhibitors
|
|
JP6466348B2
(ja)
|
2013-02-28 |
2019-02-06 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
HUE033542T2
(en)
|
2013-04-03 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
|
|
HUE040446T2
(hu)
|
2013-05-17 |
2019-03-28 |
Janssen Sciences Ireland Uc |
Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
|
|
TW202126620A
(zh)
|
2013-05-17 |
2021-07-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
WO2015011281A1
(en)
|
2013-07-25 |
2015-01-29 |
Janssen R&D Ireland |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
WO2015081463A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Egfr inhibitor forms
|
|
WO2015083059A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Forms of the egfr inhibitor
|
|
WO2015085482A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Novartis Ag |
Egfr inhibitor forms
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
JP6553059B2
(ja)
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
PL3102572T3
(pl)
|
2014-02-06 |
2019-04-30 |
Janssen Sciences Ireland Uc |
Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
|
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
IL291000B2
(en)
*
|
2014-03-20 |
2024-04-01 |
Capella Therapeutics Inc |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
US10195208B2
(en)
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
WO2016055916A1
(en)
|
2014-10-06 |
2016-04-14 |
Novartis Ag |
Therapeutic combination for the treatment of cancer
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
TWI706958B
(zh)
|
2015-03-10 |
2020-10-11 |
美商艾杜諾生物科技公司 |
活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
|
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
WO2016185333A1
(en)
|
2015-05-15 |
2016-11-24 |
Novartis Ag |
Methods for treating egfr mutant cancers
|
|
CA2986522A1
(en)
*
|
2015-05-22 |
2016-12-01 |
Novartis Ag |
Pharmaceutical compositions
|
|
HK1252693A1
(zh)
|
2015-06-30 |
2019-05-31 |
Dana Farber Cancer Institute, Inc. |
Egfr抑制剂及其使用方法
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
RU2018105846A
(ru)
*
|
2015-07-29 |
2019-08-28 |
Новартис Аг |
Комбинация антагониста pd-1 с ингибитором egfr
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
ES2911888T3
(es)
*
|
2015-09-18 |
2022-05-23 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos
|
|
WO2017053537A1
(en)
*
|
2015-09-23 |
2017-03-30 |
Capella Therapeutics, Inc. |
Benzimidazoles for use in the treatment of cancer and inflammatory diseases
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
AR106192A1
(es)
|
2015-09-29 |
2017-12-20 |
Novira Therapeutics Inc |
Formas cristalinas de un agente antiviral contra la hepatitis b
|
|
PT3370768T
(pt)
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
WO2017175156A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
JP2019510795A
(ja)
*
|
2016-04-08 |
2019-04-18 |
ノバルティス アーゲー |
新規の治療的使用
|
|
WO2017181141A2
(en)
|
2016-04-15 |
2017-10-19 |
Novira Therapeutics, Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
US20170321285A1
(en)
*
|
2016-05-03 |
2017-11-09 |
The Texas A&M University System |
Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CN107663170B
(zh)
*
|
2016-07-29 |
2020-02-11 |
广东东阳光药业有限公司 |
制备贝西沙星中间体化合物的方法
|
|
CA2939286A1
(en)
*
|
2016-08-17 |
2018-02-17 |
Pharmascience Inc. |
Spirocyclic containing compounds and pharmaceutical uses thereof
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018112090A1
(en)
*
|
2016-12-13 |
2018-06-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of treating cancers containing fusion genes
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
CN106946779A
(zh)
*
|
2017-02-13 |
2017-07-14 |
广州仁恒医药科技股份有限公司 |
一种r‑3‑氨基‑六氢氮杂*的制备方法
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
SG11201913249SA
(en)
|
2017-08-03 |
2020-02-27 |
Novartis Ag |
Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
|
|
EP3661519A1
(en)
|
2017-08-03 |
2020-06-10 |
Novartis AG |
Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
|
|
CN109721605B
(zh)
*
|
2017-10-31 |
2022-03-11 |
维眸生物科技（上海）有限公司 |
一种免疫细胞迁徙抑制剂
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
JP7313364B2
(ja)
*
|
2018-02-21 |
2023-07-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
|
|
SG11202007097QA
(en)
|
2018-03-14 |
2020-08-28 |
Janssen Sciences Ireland Unlimited Co |
Capsid assembly modulator dosing regimen
|
|
US20210145842A1
(en)
|
2018-04-18 |
2021-05-20 |
Novartis Ag |
New therapeutic uses
|
|
CN118286225A
(zh)
*
|
2018-04-26 |
2024-07-05 |
辉瑞公司 |
作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
CN109369620B
(zh)
*
|
2018-12-22 |
2020-04-14 |
山东大学 |
吡啶类化合物及其制备方法与抗胃癌应用
|
|
AU2020223865A1
(en)
|
2019-02-22 |
2021-07-15 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
US12522615B2
(en)
|
2019-06-24 |
2026-01-13 |
Boehringer Ingelheim International Gmbh |
Macrocyclic compounds and derivatives as EGFR inhibitors
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
US20240158391A1
(en)
*
|
2019-10-15 |
2024-05-16 |
Aucentra Therapeutics Pty Ltd |
Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
|
|
KR102267662B1
(ko)
|
2019-11-19 |
2021-06-22 |
한국화학연구원 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
CA3168146A1
(en)
|
2020-01-20 |
2021-07-29 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
|
|
CA3179994A1
(en)
|
2020-05-08 |
2021-11-11 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and nazartinib
|
|
WO2021235812A1
(ko)
*
|
2020-05-18 |
2021-11-25 |
웰마커바이오 주식회사 |
Ron 돌연변이와 관련된 비소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
|
|
US20230242521A1
(en)
*
|
2020-05-18 |
2023-08-03 |
Wellmarker Bio Co., Ltd. |
Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
|
|
US20230202992A1
(en)
*
|
2020-05-18 |
2023-06-29 |
Wellmarker Bio Co., Ltd. |
Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
CN113880804A
(zh)
*
|
2020-07-01 |
2022-01-04 |
微境生物医药科技(上海)有限公司 |
新型苯并咪唑化合物
|
|
AU2021360412A1
(en)
*
|
2020-10-12 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
JP7805363B2
(ja)
|
2020-11-02 |
2026-01-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
IL303834A
(en)
|
2020-12-23 |
2023-08-01 |
Genzyme Corp |
4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
|
|
MX2023013690A
(es)
*
|
2021-05-17 |
2024-01-30 |
Hk Inno N Corp |
Derivado de benzamida, metodo para preparar el mismo, y composicion farmaceutica para la prevencion o tratamiento del cancer que contiene el mismo como ingrediente activo.
|
|
WO2022242712A1
(zh)
*
|
2021-05-21 |
2022-11-24 |
深圳市塔吉瑞生物医药有限公司 |
取代的大环化合物及包含该化合物的组合物及其用途
|
|
JP2024523861A
(ja)
|
2021-06-15 |
2024-07-02 |
ジェネンテック， インコーポレイテッド |
がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
|
|
AU2022371404A1
(en)
*
|
2021-10-18 |
2024-05-23 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
KR102572664B1
(ko)
*
|
2022-02-07 |
2023-08-30 |
주식회사 인터엠 |
오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송
|
|
AU2023262556A1
(en)
|
2022-04-28 |
2024-12-05 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
US20240116926A1
(en)
|
2022-04-28 |
2024-04-11 |
Astrazeneca Ab |
Heteroaromatic compounds
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
EP4540229A1
(en)
*
|
2022-06-14 |
2025-04-23 |
Principia Biopharma Inc. |
Methods of making tolebrutinib
|
|
TW202416963A
(zh)
*
|
2022-09-02 |
2024-05-01 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｇｆｒ抑制劑及其用途
|